

Transparency in infectious disease research: a meta-research survey of specialty journals

1 **Emmanuel A. Zavalis^{1,2†}, Despina G. Contopoulos-Ioannidis^{3†}, John P.A. Ioannidis^{2,4*}**

2 ¹Department of Learning Informatics Management and Ethics, Karolinska Institutet, Stockholm,
3 Sweden

4 ²Meta-Research Innovation Center at Stanford (METRICS), Stanford University, Stanford, CA, USA

5 ³Division of Infectious Diseases, Department of Pediatrics, Stanford University School of Medicine,
6 Stanford, CA, USA

7 ⁴Stanford Prevention Research Center, Department of Medicine, and Department of Epidemiology
8 and Population Health, Stanford University School of Medicine, Stanford, CA, USA

9 *** Correspondence:**

10 Corresponding Author

11 jioannid@stanford.edu

12 †These authors contributed equally to this work and share first authorship

13 **Keywords: Infectious Disease, Transparency, Reproducibility, Rigor, Meta-Research, Meta-**
14 **epidemiology**

15 Word count: 3845

16 Number of tables and figures: 4 tables, 1 figure, 30 supplemental figures, 2 supplemental tables, 1
17 supplemental file

18

19 **Abstract**

20 **Introduction:** Infectious diseases carry a large global burden and have implications for society at
21 large. Therefore, reproducible, transparent research is extremely important. To assess the current
22 state of transparency in this field, we investigated code sharing, data sharing, protocol registration,
23 conflict of interest and funding disclosures in articles published in the most influential infectious
24 disease journals.

25 **Methods:** We evaluated transparency indicators in the 5340 PubMed Central Open Access (PMC
26 OA) articles published in 2019 or 2021 in the 9 most-cited specialty journals in infectious disease.
27 We used a previously validated text-mining R package, *rtransparent*. The approach was manually
28 validated for a random sample of 200 articles for which study characteristics were also extracted in
29 detail. Main comparisons assessed 2019 versus 2021 articles, 2019 versus 2021 non-COVID-19
30 articles, and 2021 non-COVID-19 articles versus 2021 COVID-19 articles.

31 **Results:** A total of 5340 articles were evaluated (1860 published in 2019 and 3480 in 2021 (of which
32 1828 on COVID-19)). Text-mining identified code sharing in 98 (2%) articles, data sharing in 498
33 (9%), registration in 446 (8%), conflict of interest disclosures in 4209 (79%) and funding disclosures
34 in 4866 (91%). There were substantial differences across the 9 journals in the proportion of articles
35 fulfilling each transparency indicator: 1-9% for code sharing, 5-25% for data sharing, 1-31% for
36 registration, 7-100% for conflicts of interest, and 65-100% for funding disclosures. There were no
37 major differences between articles published in 2019 and non-COVID-19 articles in 2021. In 2021,
38 non-COVID-19 articles had more data sharing (12%) than COVID-19 articles (4%). Validation-
39 corrected imputed estimates were 3% for code sharing, 11% for data sharing, 8% for registrations,
40 79% for conflict of interest disclosures and 92% for funding disclosures.

41 **Conclusion:** Data sharing, code sharing, and registration are very uncommon in infectious disease
42 specialty journals. Increased transparency is required.

43

44

45 **1 Introduction**

46 Infectious diseases are an important field in medicine, epidemiology, and public health across a
47 spectrum that spans basic science, translational research, clinical and population-level applications.
48 The global burden of infectious disease has been large, with a higher share in less developed
49 countries(1–4). With the advent of the COVID-19 pandemic the developed world was sensitized to
50 the field with awakened interest and its funding and research output increased rapidly(5–7). The rigor
51 and reliability of the evidence generated in the field of infectious diseases therefore has major
52 implications for the health of individuals, populations, and societies at large. In this regard,
53 transparency features, such as sharing of data and code, availability of pre-registered protocols, as
54 well as reporting of conflicts of interest and funding, can be fundamental in evaluating the evidence
55 obtained by research investigations in infectious diseases (8–10). Previous work has assessed these
56 transparency indicators in depth in infectious disease models specifically, a type of research that
57 became highly popular and influential during the COVID-19 pandemic(11). It was found that the
58 majority of such epidemiological modeling studies do not share their data and/or their code, and very
59 few have registered protocols. The vast majority of published articles have conflict of interest and
60 funding statements, but it is not clear whether the information reported is complete(12,13).

61 Infectious disease research, nevertheless, encompasses a very large range of study designs and
62 research efforts. It is unknown whether transparency is high for these diverse types of designs and
63 whether there are some study features and characteristics that may be associated with better or worse
64 performance of the published articles in terms of transparency indicators. More importantly, the
65 COVID-19 pandemic was a crash test for many scientific fields, and most prominently this applied
66 par excellence to the field of infectious diseases. Massive publication volume may not necessarily
67 have been accompanied by high quality and/or transparency(5,14,15). It is important to study
68 whether the infectious diseases literature published during the pandemic was different in this regard
69 compared to the pre-pandemic papers published in the same journals that specialize on infectious
70 diseases.

71 Here, we present the results of meta-epidemiological assessment of transparency indicators of recent
72 articles published in the major infectious disease specialty journals, comparing the transparency
73 performance of these journals in the pre-pandemic (2019) and in the COVID-19 pandemic (2021)
74 period.

75 **2 Materials and Methods**

76 The protocol of the study was pre-registered in Open Science Framework
77 (<https://doi.org/10.17605/OSF.IO/FYZPX>).

78 **2.1 Study sample**

79 We examined the papers published in 2019 and 2021 by the 9 specialty journals that received the
80 largest total number of citations in infectious disease research, according to the InCites Journal
81 Citation Reports (JCR)(16) in the respective specialty category (see Supplementary Table 1). We
82 focused on papers indexed in the PubMed Central Open Access (PMC OA) subset of PubMed,
83 similar to previous work, since these are the papers that can be massively downloaded for in depth
84 text mining of transparency indicators. The specific journals are tabulated in Supplementary Table 1

85 along with the number of citations that they received based on the latest JCR edition(16). We aimed
86 to focus on original articles and reviews, excluding letters, editorials, and study protocols.

87 Supplementary Table 1

88 **2.2 Search query**

89 The search was performed on PubMed on the 14th of September 2022 using the query: "pubmed pmc
90 open access"[Filter] AND ("clin infect dis"[Journal] OR "j infect dis"[Journal] OR "lancet infect
91 dis"[Journal] OR "infect immun"[Journal] OR "emerg infect dis"[Journal] OR "j antimicrob
92 chemother"[Journal] OR "clin microbiol infect"[Journal] OR "bmc infect dis"[Journal] OR "int j
93 infect dis"[Journal]) AND ("journal article"[Publication Type]) NOT ("editorial"[Publication Type]
94 OR "letter"[Publication Type] OR "clinical trial protocol"[Publication Type]) AND "hasabstract"[All
95 Fields] AND "english"[Language] AND (ffrft[Filter]) AND (2019:2019[pdat] OR 2021:2021[pdat])

96 **2.3 Data extraction**

97 **2.3.1 Text mining**

98 For each eligible article we used PubMed to extract information on metadata that included PMID,
99 PMCID, publication year, journal name, affiliation and the R package *rtransparent*(17) to extract the
100 following transparency indicators: (i) code sharing (ii) data sharing (iii) protocol (pre-)registration,
101 (iv) conflicts of interest and (v) funding statements. *rtransparent* was also used to retrieve whether a
102 journal was original research or a review, so as to be eligible. *rtransparent* searches through the full
103 text of the papers for specific words or phrases that strongly suggest that the aforementioned
104 transparency indicators are present in that particular paper. The program uses regular expressions to
105 adjust for variations in expressions. For details on the exact code and terms/phrases captured by
106 *rtransparent*, see(17).

107 **2.3.2 Manually extracted characteristics**

108 From a random sample of 200 articles (2019 and 2021) we extracted additional characteristics
109 manually. The manually extracted characteristics were meta-data (country of the first and last author,
110 length of the article, number of tables, figures and appendices); study design; type of pathogen/
111 disease/ drug or vaccine studied; and, for clinical studies, whether a study was interventional or not,
112 and its primary focus if interventional (therapy or prevention). Finally, we extracted information
113 about the study population including age group, human vs animal work and sample size (for
114 systematic reviews we used the number of included articles). See our protocol of our study
115 (<https://doi.org/10.17605/OSF.IO/FYZPX>) for details on items extracted and options for each item.

116 **2.4 Primary comparisons and statistical analysis**

117 We considered three primary comparisons that were conducted using Fisher's exact tests for each
118 transparency indicator separately. For analysis of associations, we used a statistical significance
119 threshold of 0.005(18). The analysis code was written in R 4.2.1(19).

120 We compared transparency indicators for 2019 versus 2021, 2019 versus 2021 non-COVID-19, and
121 2021 COVID-19 versus 2021 non-COVID-19 articles in order to evaluate whether there has been an
122 improvement over time, and whether COVID-19 articles differed from non-COVID-19 ones. These
123 comparisons were performed with and without stratification for journal, since it was possible that
124 differences are seen across specific journals. Fisher's exact tests were used to test our unstratified

125 comparisons. The tests were performed for each transparency indicator separately. To stratify and
126 account for journals we had originally anticipated to perform random-effects meta-analyses for odds
127 ratios, stratifying the overall sample by journal. However, there was no significant between-journal
128 heterogeneity for almost all analyses (with rare exceptions), and some cells in 2x2 tables for some
129 journals had very small numbers and zeros. Therefore, we preferred as the default the fixed effects
130 analysis with a 0.5 correction for 2x2 tables with zero cells, but random effects are also presented.

131 The COVID-19 articles were identified by categorizing all retrieved articles when combining the
132 main search query to the following query in PubMed: SARS-CoV-2 OR ‘coronavirus 2’ OR ‘corona
133 virus 2’ OR covid-19 OR {novel coronavirus} OR {novel corona virus} OR 2019-ncov OR covid
134 OR covid19 OR ncovid-19 OR ‘coronavirus disease 2019’ OR ‘corona virus disease 2019’ OR
135 corona-19 OR SARS-nCoV OR ncov-2019 used in prior research(20).

136 **2.5 Secondary comparisons**

137 Secondary comparisons of the transparency across the manually extracted characteristics were
138 performed. The comparisons were descriptive rather than testing specific hypotheses and they
139 focused on code sharing, data sharing and registration since it was expected (and indeed documented
140 eventually) that the vast majority of articles would have a place-holder statement for conflict of
141 interest and funding.

142 **2.6 Manual validation**

143 In order to validate the performance of the automated text mining algorithms, we evaluated the 200
144 randomly selected articles manually for the presence of each of the 5 text mined indicators. This
145 aimed to identify for each indicator, the number of false positives (indicator identified in text mining,
146 but not manually) and false negatives (indicator not identified in text mining but identified
147 manually).

148 This information allowed a correction of the estimates of the proportion of articles that satisfy each of
149 the transparency indicators. As in previous work(11), the corrected proportion $C(i)$ of publications
150 satisfying an indicator i was obtained by $U(i) \times TP + (1 - U(i)) \times FN$, where $U(i)$ is the uncorrected
151 proportion detected by the automated algorithm, TP is the proportion of true positives (proportion of
152 those manually verified to satisfy the indicator among those identified by the algorithm as satisfying
153 the indicator), and FN is the proportion of false negatives (proportion of those manually found to
154 satisfy the indicator among those categorized by the algorithm not to satisfy the indicator).

155 In the 200 randomly selected articles, moreover, whenever there was a conflict of interest disclosure
156 statement, we noted whether no conflict was disclosed (e.g. “the authors have no conflicts to
157 disclose”). Similarly, for funding, we noted whether the statement stated that no funding was received,
158 or specific funding was disclosed.

159 **2.7 Amendments to the original protocol**

160 1. During the manual validation procedure, we noted that a number of articles in Clinical Infectious
161 Diseases and in Journal of Infectious Diseases were available in PMC only in a watermarked pdf
162 version that could not be accessed by the automated algorithm. We therefore went back and
163 identified all 293 articles in our sample that could not be read by the automated algorithms and
164 manually extracted them for the 5 transparency indicators.

165 2. Fixed effects were preferred over random effects for the journal-stratified analyses, as discussed
166 above. They practically give identical results when the estimated between-study variance is 0 (in the
167 vast majority of cases). Fixed effects is preferable given the very small numbers in some 2x2 table
168 cells and acceptable given the lack of between-study heterogeneity (with few exceptions, as
169 discussed below). Random effects estimates are also provided.

170 **3 Results**

171 **3.1 Overall study sample**

172 The search query retrieved 5701 articles from the PubMed Central Open Access subset of which 361
173 were neither an original article nor a systematic review (using *rtransparent* classification of articles)
174 and were excluded. Of the 5340 eligible papers, 1860 were published in 2019 and 3480 in 2021. 19
175 papers published in 2019 were retrieved by the COVID-19 search query, but upon in depth
176 examination none proved to be COVID-19 research but reflected a 1% false COVID-19 assignment
177 error. 1828/3480 articles published in 2021 were retrieved with the COVID-19 query (See Figure 1).

178 Figure 1

179 Of the 5340 publications, there were 1956 (37%) from BMC Infectious Diseases, 850 (16%) from
180 Clinical Infectious Diseases, 194 (4%) from Clinical Microbiology and Infection, 912 (17%) from
181 Emerging Infectious Diseases, 107 (2%) from Infection and Immunity, 585 (11%) from International
182 Journal of Infectious Diseases, 212 (4%) from Journal of Antimicrobial Chemotherapy, 383 (7%)
183 from Journal of Infectious Diseases, and 141(3%) from Lancet Infectious Diseases. The proportion
184 of COVID-19 publications in 2021 ranged from 0% for Infection and Immunity to 88% for
185 International Journal of Infectious Diseases.

186 **3.2 Transparency indicators**

187 In the examined sample of 5340 articles, 98 (2%) shared code, 498 (9%) shared data, 446 (8%) were
188 registered, 4209 (79%) contained a conflict of interest statement, and 4866 (91%) a funding
189 statement.

190 When stratifying the transparency indicators across journal there were observable differences across
191 publications in the different journals with some outliers. For instance, Lancet Infectious Diseases had
192 9% articles that shared code whilst the others had rates around 2%. For data sharing, Infection and
193 Immunity was an outlier with 25% data sharing articles, while Emerging Infectious Diseases and
194 Journal of Antimicrobial Chemotherapy were at 14-15% and all other journals just had 5-10% data
195 sharing. There was also a clear difference in registration rates, with the highest rates in Lancet
196 Infectious Diseases (31%) and the lowest in Infection and Immunity (1%). Rates of conflict of
197 interest disclosures varied widely from 7% in Emerging Infectious Diseases to 100% in BMC
198 Infectious Diseases. Funding disclosures varied modestly, from 65% in Emerging Infectious Diseases
199 to 100% in BMC Infectious Diseases (see Table 1).

200 Table 1.

201 The primary comparisons of transparency indicators between 2019 and 2021 showed a statistically
202 significant increase in code sharing, a decrease in data sharing, and a decrease in funding disclosures,
203 but the differences were very modest in absolute magnitude (all $\leq 4\%$). Comparing the samples from
204 2019 and the non-COVID-19 papers from 2021 yielded similar rates of transparency in these two

205 years across all five transparency indicators. Finally, the comparison of the 2021 non-COVID-19
206 papers to the COVID-19 papers published in the same year showed a statistically significantly higher
207 rate of data sharing and a lower rate of conflict of interest disclosures in non-COVID-19 papers (see
208 Table 2).

209 Table 2.

210 Meta-analysis of the data stratified per journal showed no statistically significant heterogeneity in
211 any of the comparisons with the exception of funding disclosures ($I^2=72\%$ (44%-86%)) and
212 registration ($I^2=65\%$ (22%-85%)) for the comparison of COVID-19 versus non-COVID-19 articles in
213 2021. Meta-analytic results were largely similar to those inferred by Fisher's exact tests without
214 stratifying for journal (see Table 3).

215 Table 3.

216 In Table 4 we have tabulated the transparency according to the groups of the main comparisons and
217 journal and performed stratified Fisher's exact tests for all hypotheses and all journals separately for
218 each indicator.

219 Table 4.

220 **3.3 Manually assessed sample of 200 randomly selected articles**

221 In the random sample of 200 articles that were examined in depth, the most common countries of
222 first and last author were US and China and the collectively accounted for about a third of the
223 articles. Most studies were classified as observational (34%) or epidemiologic surveillance (22%).
224 The large majority of studies (88%) addressed a specific pathogen. Most studies (55%) used neither
225 p-values nor confidence intervals in their abstract. Most studies were on humans (80%) and age
226 groups represented were very diverse. 166 of the 200 (83%) studies could be characterized as clinical
227 studies. Among the clinical studies, 42 (25%) were interventional and 124 (75%) were non-
228 interventional. The primary focus of the study was epidemiology in 76 (38%) articles, therapy in 34
229 (17%), diagnosis in 21 (11%), and prevention in 14 (7%) articles. 13 (7%) had a focus on risk and 9
230 (5%) had a pathophysiological focus. Details on the characteristics of the manually assessed random
231 sample appear in the Supplementary Table 2.

232 The same supplementary table 2 also shows details on the presence of code sharing, data sharing, and
233 registration in the 200 papers, according to these characteristics. As shown, no characteristic seemed
234 to be associated with markedly higher rates of code sharing or data sharing, perhaps with the
235 exception of code sharing for predictive models (28%), but numbers are very thin to make robust
236 inferences. For registration, 10/10 clinical trials (100%) and 4/13 (31%) of systematic reviews were
237 registered, but only 3 other studies were registered among the remaining 177 articles.

238 **3.4 Manual validation**

239 The rate of false positives of the automated algorithms was 0/3 (0%) for code sharing, 1/12 (8%) for
240 data sharing, 1/19 (5%) for registration, 0/145 (0%) for conflict of interest disclosures and 0/166
241 (0%) for funding disclosures. On the other hand the false negative rate was 2/180 (1%) for code
242 sharing, 4/171 (2%) for data sharing, 1/164 (1%) for registration, 1/38 (3%) for conflict of interest
243 disclosures and 1/17 (6%) for funding disclosures.

244 41/182 (23%) of funding disclosures practically stated that there was no funding for the study.
245 117/162 (72%) of the conflict of interest statements practically declared that there was no conflict of
246 interest.

247 Adjusting for the manual validation results, the corrected proportions of transparency indicators were
248 3% for code sharing, 11% for data sharing, 8% for registrations, 79% for conflict of interest
249 disclosures and 92% for funding disclosures.

250 **4 Discussion**

251 This evaluation of 5340 articles in infectious disease research published in 2019 and in 2021 in the
252 top 9 specialty journals with respects to impact showed that only a small minority of articles shared
253 code or data. Study registration was also rare, and it pertained almost exclusively to clinical trials and
254 some systematic reviews. Conflict of interest and funding disclosures were, conversely, very
255 common. There was no major change in absolute magnitude in the proportion of articles that
256 satisfied these transparency indicators during 2021 (a pandemic year) versus 2019 (a pre-pandemic
257 years). COVID-19 articles had modestly lower rates of data sharing.

258 In a previous evaluation(11) we had studied 1338 articles from 2019 and 2021 and we had showed
259 that approximately a quarter of publications shared code, and a modestly higher proportion shared
260 data in studies of infectious disease modelling. High rates of conflict of interest and funding
261 disclosures were also observed in the same study (around 90% for both). Registrations on the other
262 hand were below 1% in that sample. The disparities are likely due to the difference in the study
263 characteristics; infectious disease models were very sparse in our sample. Most of the studies that we
264 evaluated were clinical, and since registration is more common in clinical trials and clinical research
265 overall(21) this has likely affected the overall average in our included sample. However, registration
266 is distinctly uncommon outside of clinical trials, with the exception of some systematic reviews.
267 Moreover, code and data sharing are expected to be more common in modeling studies, where such
268 sharing is indispensable, while these research practices remain quite rare in the bulk of clinical and
269 epidemiological research that comprises the vast volume of papers published in infectious disease
270 journals.

271 The numbers regarding code sharing are similar to the overall assessments previously performed by
272 Serghiou et al.(17), but the rate of data sharing and registration was higher when studying the entire
273 PubMed Central Open Access subset across all scientific disciplines. Iqbal et al.(22), showed similar
274 rates of transparency in publications indexed in 2014 when they studied a random sample of 441
275 PubMed articles between 2000 and 2014. Overall, infectious disease specialty journals seem to be
276 performing below the average of biomedical journals in data sharing and registration.

277 Code and data sharing are critical elements of computational reproducibility. They are an essential
278 part of most conducted research as it allows the reanalysis and the assessment of the methods section
279 for potential errors or non-disclosed analytical approaches that may affect the study results. We
280 should acknowledge that code sharing may not be applicable to some types of infectious disease
281 articles where there are no quantitative computational parts. Also data sharing may need to take into
282 account the specific circumstances of the research, e.g. consent requirements and the need for
283 deidentification, that may be common in infectious disease research, especially clinical studies.
284 Nevertheless, more transparent sharing in general is desirable. Sharing practices can also maximize
285 the future use of the data and enhance the value of the collected information(23). The absence of
286 sharing affects the trustworthiness of the analytical approaches in published research. Many efforts

287 have been directed toward increasing reproducibility through increased sharing. These include the
288 changes in journal policy for Science regarding data sharing and the new regulations regarding data
289 sharing that the NIH aims to implement in 2023 (8,24,25), further showing the importance of this
290 aspect of transparency.

291 Registration, on the other hand, is key in research that aims to inform clinical practice and policy and
292 to avoid “vibration of effects”(26,27), i.e. instability in the results due to post-hoc, selective choices
293 of statistical analyses and reporting bias, choosing which analyses and outcomes to report. A sensible
294 prospective registration process may increase the reliability of the results from observational as well
295 as interventional research and one may compare notes between registered protocols and subsequent
296 results that are made available(10,28–31). Nevertheless, registration remains very uncommon outside
297 of randomized trials and systematic reviews.

298 **4.1 Limitations**

299 Our meta-research assessment has certain limitations. First, the existence of transparency indicators
300 in the text of a published article does not guarantee the informational value of the statements. For
301 example, for code sharing and data sharing, one would have to examine in depth whether the code
302 and the data are not only accessible but functional and contain all the information needed to use
303 them.

304 Second, the veracity of some statements of transparency may also be brought into question,
305 especially for conflict of interest and funding disclosures. Disclosures are notoriously difficult to
306 verify for their completeness and accuracy, despite the emerging availability of some resources such
307 as the Centers for Medicare & Medicaid Services Open Payments database(32) in the US. Many
308 assessments have been performed with this data and shown a worrying amount of undisclosed
309 conflicts in opioid prescription(33), dermatology(12) and otolaryngology(13) guidelines among
310 others. The research and clinical practice of infectious diseases is not exempt from this pattern. One
311 well known example is the so called “Lyme wars”, where conflicts remained unreported and affected
312 developed clinical practice guidelines(34); this also led to a class action lawsuit and an investigation
313 by the Attorney General that forced IDSA to redo the Lyme guidelines. Other empirical evaluations
314 have also shown large rates of conflicts in infectious diseases in specific settings or countries, e.g. in
315 Japan (35).

316 Second, infectious disease journals vary a lot in scope and types of studies that they publish.
317 Infectious disease research spans a wide range of investigations, from in vitro studies of mice to
318 clinical research. Transparency and reproducibility challenges may differ for different types of
319 research. We used a large sample and diverse journals so as to capture this diversity, but some types
320 of studies may have been under-represented. The 9 examined journals also publish a lion’s share of
321 the papers published by infectious disease specialty journals (as characterized by JCR). However,
322 some very influential infectious disease-related studies are not published in the specialty journals of
323 the field, but in general medical and general science journals (e.g. Nature or Science) and many
324 papers on infections may appear in specialty journals outside of those focusing on infections.
325 Transparency indicators may exhibit different patterns in these journals.

326 Third, only PMC OA subset publications were included and not the full list of PubMed publications
327 from the 9 journals. There may be specific tendencies in the open access subset that leads to a
328 misrepresentation of proportions of transparency. Open access articles may be more transparent
329 overall; if so, we may have overestimated the rate of transparency in the field. Furthermore, the
330 overall rate of open access status has increased with the COVID-19 pandemic and the funders’ and

331 publishers' open sharing commitments that came as a response to the pandemic. Prior estimates have
332 shown upward of 97% of COVID-19 papers being open access publications(36–38), outpacing any
333 other field's openness and further skewing the sample.

334 Fourth, we sampled from two recent years, 2019 and 2021, where 2021 is a unique pandemic year
335 and therefore these numbers are possible to not reflect true yearly trends but mostly the covidization
336 of science that has been observed across fields and disciplines and its repercussions(5,7,20,39).
337 However, we did use a comparison focusing only on the non-COVID-19 papers in these two years.

338 Finally, some infectious disease studies are purely non-quantitative and coding analyses would make
339 little or no sense. Also registration is not necessarily feasible or appropriate for all studies.
340 Therefore, one should not expect these transparency indicators to be feasible to attain in 100% of the
341 published infectious disease articles, even under perfect transparency settings.

342 **4.2 Conclusions**

343 The repeated disconcerting finding of opacity in medical research and the reproducibility crisis may
344 be inextricably joined. Lack of transparency poses obstacles to reliable and rigorous scientific
345 research. Therefore, infectious disease specialty journals would benefit from more common adoption
346 of code and data sharing for the articles that they publish. Registration practices could also be
347 optimized in the field.

348 **5 Conflict of Interest**

349 The authors declare that the research was conducted in the absence of any commercial or financial
350 relationships that could be construed as a potential conflict of interest.

351 **6 Funding**

352 There is no funding for this project (EZ, DCI, JPAI)

353 **7 Acknowledgments**

354 None

355 **8 Data Availability Statement**

356 The code and data generated and analyzed for this study is available in
357 <https://doi.org/10.17605/OSF.IO/FYZPX> (for the code and datasets, as well as the protocol).

358 **9 References**

- 359 1. Armitage C. The high burden of infectious disease. *Nature*. 2021 Oct 28;598(7882):S9–S9.
- 360 2. Michaud CM. Global Burden of Infectious Diseases. *Encyclopedia of Microbiology*. 2009;444–
361 54.
- 362 3. Levin AT, Owusu-Boaitey N, Pugh S, Fosdick BK, Zwi AB, Malani A, et al. Assessing the burden
363 of COVID-19 in developing countries: systematic review, meta-analysis and public policy
364 implications. *BMJ Global Health*. 2022 May 1;7(5):e008477.

- 365 4. Huang G, Guo F. Loss of life expectancy due to respiratory infectious diseases: findings from the
366 global burden of disease study in 195 countries and territories 1990-2017. *J Popul Res (Canberra)*.
367 2022;39(1):1–43.
- 368 5. Ioannidis JPA, Bendavid E, Salholz-Hillel M, Boyack KW, Baas J. Massive covidization of
369 research citations and the citation elite. *Proc Natl Acad Sci U S A*. 2022 Jul
370 12;119(28):e2204074119.
- 371 6. Pai M. Covidization of research: what are the risks? *Nat Med*. 2020 Aug;26(8):1159.
- 372 7. Riccaboni M, Verginer L. The impact of the COVID-19 pandemic on scientific research in the life
373 sciences. Naudet F, editor. *PLoS ONE*. 2022 Feb 9;17(2):e0263001.
- 374 8. Stodden V, McNutt M, Bailey DH, Deelman E, Gil Y, Hanson B, et al. Enhancing reproducibility
375 for computational methods. *Science*. 2016 Dec 9;354(6317):1240–1.
- 376 9. Ioannidis JPA. Pre-registration of mathematical models. *Math Biosci*. 2022 Jan 25;345:108782.
- 377 10. Nosek BA, Ebersole CR, DeHaven AC, Mellor DT. The preregistration revolution. *Proc Natl*
378 *Acad Sci USA*. 2018 Mar 13;115(11):2600–6.
- 379 11. Zavalis EA, Ioannidis JPA. A meta-epidemiological assessment of transparency indicators of
380 infectious disease models. Chen CH, editor. *PLoS ONE*. 2022 Oct 7;17(10):e0275380.
- 381 12. Checketts JX, Sims MT, Vassar M. Evaluating Industry Payments Among Dermatology
382 Clinical Practice Guidelines Authors. *JAMA Dermatol*. 2017 Dec 1;153(12):1229.
- 383 13. Horn J, Checketts JX, Jawhar O, Vassar M. Evaluation of Industry Relationships Among
384 Authors of Otolaryngology Clinical Practice Guidelines. *JAMA Otolaryngol Head Neck Surg*.
385 2018 Mar 1;144(3):194–201.
- 386 14. Jung RG, Di Santo P, Clifford C, Prosperi-Porta G, Skanes S, Hung A, et al. Methodological
387 quality of COVID-19 clinical research. *Nat Commun*. 2021 Dec;12(1):943.
- 388 15. Abbott R, Bethel A, Rogers M, Whear R, Orr N, Shaw L, et al. Characteristics, quality and
389 volume of the first 5 months of the COVID-19 evidence synthesis infodemic: a meta-research
390 study. *BMJ Evid Based Med*. 2022 Jun;27(3):169–77.
- 391 16. Journal Impact Factor - Journal Citation Reports [Internet]. Web of Science Group. [cited
392 2022 Sep 14]. Available from: [https://clarivate.com/webofsciencegroup/solutions/journal-citation-](https://clarivate.com/webofsciencegroup/solutions/journal-citation-reports/)
393 [reports/](https://clarivate.com/webofsciencegroup/solutions/journal-citation-reports/)
- 394 17. Serghiou S, Contopoulos-Ioannidis DG, Boyack KW, Riedel N, Wallach JD, Ioannidis JPA.
395 Assessment of transparency indicators across the biomedical literature: How open is open? Bero
396 L, editor. *PLoS Biol*. 2021 Mar 1;19(3):e3001107.
- 397 18. Benjamin DJ, Berger JO, Johannesson M, Nosek BA, Wagenmakers EJ, Berk R, et al.
398 Redefine statistical significance. *Nat Hum Behav*. 2018 Jan;2(1):6–10.
- 399 19. R: The R Project for Statistical Computing [Internet]. [cited 2022 Mar 29]. Available from:
400 <https://www.r-project.org/>

- 401 20. Ioannidis JPA, Salholz-Hillel M, Boyack KW, Baas J. The rapid, massive growth of COVID-
402 19 authors in the scientific literature. *R Soc open sci*. 2021 Sep;8(9):210389.
- 403 21. Al-Durra M, Nolan RP, Seto E, Cafazzo JA. Prospective registration and reporting of trial
404 number in randomised clinical trials: global cross sectional study of the adoption of ICMJE and
405 Declaration of Helsinki recommendations. *BMJ*. 2020 Apr 14;m982.
- 406 22. Iqbal SA, Wallach JD, Khoury MJ, Schully SD, Ioannidis JPA. Reproducible Research
407 Practices and Transparency across the Biomedical Literature. *PLoS Biol*. 2016
408 Jan;14(1):e1002333.
- 409 23. Pratt B, Bull S. Equitable data sharing in epidemics and pandemics. *BMC Med Ethics*. 2021
410 Dec;22(1):136.
- 411 24. Stodden V, Guo P, Ma Z. Toward Reproducible Computational Research: An Empirical
412 Analysis of Data and Code Policy Adoption by Journals. *PLoS One*. 2013;8(6):e67111.
- 413 25. Kozlov M. NIH issues a seismic mandate: share data publicly. *Nature*. 2022 Feb
414 16;602(7898):558–9.
- 415 26. Patel CJ, Burford B, Ioannidis JPA. Assessment of vibration of effects due to model
416 specification can demonstrate the instability of observational associations. *J Clin Epidemiol*. 2015
417 Sep;68(9):1046–58.
- 418 27. Palpacuer C, Hammas K, Duprez R, Laviolle B, Ioannidis JPA, Naudet F. Vibration of effects
419 from diverse inclusion/exclusion criteria and analytical choices: 9216 different ways to perform an
420 indirect comparison meta-analysis. *BMC Med*. 2019 Dec;17(1):174.
- 421 28. Dal-Ré R, Ioannidis JP, Bracken MB, Buffler PA, Chan AW, Franco EL, et al. Making
422 prospective registration of observational research a reality. *Sci Transl Med*. 2014 Feb
423 19;6(224):224cm1.
- 424 29. Loder E, Groves T, MacAuley D. Registration of observational studies. *BMJ*. 2010 Feb
425 18;340(feb18 2):c950–c950.
- 426 30. The Registration of Observational Studies—When Metaphors Go Bad. *Epidemiology*. 2010
427 Sep;21(5):607–9.
- 428 31. Goldacre B, DeVito NJ, Heneghan C, Irving F, Bacon S, Fleminger J, et al. Compliance with
429 requirement to report results on the EU Clinical Trials Register: cohort study and web resource.
430 *BMJ*. 2018 Sep 12;k3218.
- 431 32. Home | OpenPayments [Internet]. [cited 2022 Nov 8]. Available from:
432 <https://openpaymentsdata.cms.gov/>
- 433 33. Spithoff S, Leece P, Sullivan F, Persaud N, Belesiotis P, Steiner L. Drivers of the opioid
434 crisis: An appraisal of financial conflicts of interest in clinical practice guideline panels at the peak
435 of opioid prescribing. Lexchin J, editor. *PLoS ONE*. 2020 Jan 24;15(1):e0227045.


- 436 34. Johnson L, Stricker RB. Attorney General forces Infectious Diseases Society of America to
437 redo Lyme guidelines due to flawed development process. *Journal of Medical Ethics*. 2009 May
438 1;35(5):283–8.
- 439 35. Saito H, Tani Y, Ozaki A, Sawano T, Shimada Y, Yamamoto K, et al. Financial ties between
440 authors of the clinical practice guidelines and pharmaceutical companies: an example from Japan.
441 *Clinical Microbiology and Infection*. 2019 Nov;25(11):1304–6.
- 442 36. Arrizabalaga O, Otaegui D, Vergara I, Arrizabalaga J, Méndez E. Open Access of COVID-
443 19-related publications in the first quarter of 2020: a preliminary study based in PubMed.
444 *F1000Res*. 2020;9:649.
- 445 37. Chiarelli, Andrea, Loffreda, Lucia, Cox, Eleanor, Johnson, Rob, Ferguson, Christine,
446 Vignola-Gagné, Etienne, et al. From intent to impact: Investigating the effects of open sharing
447 commitments [Internet]. Zenodo; 2022 Jun [cited 2022 Nov 8]. Available from:
448 <https://zenodo.org/record/7003684>
- 449 38. Van Noorden R. COVID research is free to access — but for how long? *Nature*. 2022 Nov
450 3;611(7934):23–23.
- 451 39. The Lancet Infectious Diseases. Transitioning to endemicity with COVID-19 research. *The*
452 *Lancet Infectious Diseases*. 2022 Mar;22(3):297.

453

454

455 **Tables and Figures**

456 Figure 1. Study selection flowchart



457

458 Table 1. Transparency indicators stratified across journal

Journal	Total N(%)	Code sharing N(%)	Data sharing N(%)	Registration N(%)	Conflict of Interest N(%)	Funding N(%)
Total	5340	98(2)	498(9)	446(8)	4209(79)	4866(91)
BMC Infect Dis	1956(37)	28(1)	199(10)	177(9)	1956(100)	1956(100)
Clin Infect Dis	850(16)	16(2)	40(5)	103(12)	824(97)	776(91)
Clin Microbiol Infect	194(4)	0(0)	11(6)	23(12)	143(74)	167(86)
Emerg Infect Dis	912 (17)	14(2)	136(15)	6(1)	61(7)	589(65)
Infect Immun	107(2)	2(2)	27(25)	1(1)	57(53)	106(99)

Int J Infect Dis	585(11)	12(2)	27(5)	26(4)	569(97)	571(98)
J Antimicrob Chemother	212(4)	2(1)	29(14)	20(9)	77(36)	205(97)
J Infect Dis	383(7)	11(3)	18(5)	46(12)	381(99)	370(97)
Lancet Infect Dis	141 (3)	13(9)	11(8)	44(31)	141(100)	126(89)

459

460 Table 2. Primary comparisons of transparency indicators

N=5340	Total	Code sharing N(%)	Data sharing N(%)	Registration N(%)	Conflict of Interest N(%)	Funding N(%)
2019	1860	19(1)	219(12)	168(9)	1439(77)	1731(93)
2021	3480	79(2)	279(8)	278(8)	2770(80)	3135(90)
non-COVID-19	1652(37)	27(2)	204(12)	152(9)	1280(77)	1507(91)
COVID-19	1828(53)	52(3)	75(4)	126(7)	1490(82)	1628(89)
Fisher's exact test p-values						
2019 vs 2021		0.0009	1.45×10^{-5}	0.19	0.06	0.0002
2019 vs 2021 non-COVID-19		0.14	0.60	0.86	0.94	0.04
2021 non-COVID-19 vs 2021 COVID-19		0.02	$< 2.2 \times 10^{-16}$	0.012	0.004	0.04

461

462

463 Table 3. Meta-analyses of primary comparisons

Summary	Summary OR(95%CI) by fixed effects	Summary OR(95%CI) by random effects	Heterogeneity I ² % (95% CI)	Heterogeneity p-value
Code sharing (2021 v. 2019)	1.78(1.06-2.98)	1.78(1.06-2.98)	0(0-65)	0.66
Code sharing (2021 non-COVID-19 v. 2019)	1.62(0.87-3.01)	1.62(0.87-3.01)	0(0-65)	0.7
Code sharing (2021 COVID-19 v. 2021 non-COVID-19)	1.65(0.98-2.75)	1.65(0.98-2.75)	22(0-65)	0.24
Data sharing (2021 v. 2019)	0.77(0.64-0.94)	0.77(0.64-0.94)	15(0-57)	0.31
Data sharing (2021 non-COVID-19 v. 2019)	1.07(0.87-1.31)	1.10(0.86-1.40)	0(0-65)	0.44
Data sharing (2021 COVID-19 v. 2021 non-COVID-19)	0.36(0.26-0.50)	0.36(0.24-0.53)	4(0-66)	0.40
Registration (2021 v. 2019)	0.83(0.67-1.03)	0.82(0.63-1.07)	0(0-65)	0.49
Registration (2021 non-COVID-19 v. 2019)	1.00(0.79-1.28)	1.01(0.79-1.28)	0(0-65)	0.43
Registration (2021 COVID-19 v. 2021 non-COVID-19)	0.65(0.49-0.87)	0.78(0.43-1.42)	72(44-86)	<0.01
COI disclosures (2021 v. 2019)	1.08 (0.77-1.51)	1.08(0.77-1.51)	40(0-75)	0.13
COI disclosures (2021 non-COVID-19 v. 2019)	1.16(0.80-1.68)	1.16(0.80-1.68)	20(0-83)	0.29

COI disclosures (2021 COVID-19 v. 2021 non-COVID-19)	0.90(0.56-1.42)	0.81(0.44-1.49)	37(0-73)	0.15
Funding disclosures (2021 v. 2019)	0.67(0.53-0.86)	0.60(0.36-0.98)	27(0-67)	0.21
Funding disclosures (2021 non-COVID-19 v. 2019)	0.72(0.54-0.97)	0.72(0.54-0.97)	5(0-72)	0.39
Funding disclosures (2021 COVID-19 v. 2021 non-COVID-19)	0.84(0.63-1.11)	0.65(0.32-1.32)	65(22-85)	<0.01

464

465 Table 4. Transparency indicators stratified for Journal, Year and COVID-19 status.

Journal, Year and COVID-19 status	Total	Code sharing N(%)	Data sharing N(%)	Registration N(%)	Conflict of Interest N(%)	Funding N(%)
BMC Infect Dis 2019	907	7(1)	104(11)	84(9)	907(100)	907(100)
BMC Infect Dis 2021 non-COVID-19	757	12(2)	78(10)	66(9)	757(100)	757(100)
BMC Infect Dis 2021 COVID-19	292	9(3)	17(6)	27(9)	292(100)	292(100)
BMC Infect Dis 2021	1049	21(2)	95(9)	93(9)	1049(100)	1049(100)
Clin Infect Dis 2019	233	0(0)	11(5)	0(0)	233(100)	225(97)
Clin Infect Dis 2021 non-COVID-19	248	5(2)	19(8)	48(19)	248(100)	236(95)
Clin Infect Dis 2021 COVID-19	369	11(3)	10(3)	18(5)	343(93)	315(85)
Clin Infect Dis 2021	617	16(3)	29(5)	66(11)	591(96)	551(89)
Clin Microbiol Infect 2019	22	0(0)	2(9)	3(14)	20(91)	20(91)
Clin Microbiol Infect 2021 non-COVID-19	11	0(0)	2(18)	1(9)	7(64)	10(91)
Clin Microbiol Infect 2021 COVID-19	161	0(0)	7(4)	19(12)	116(72)	137(85)
Clin Microbiol Infect 2021	172	0(0)	9(5)	20(12)	123(72)	147(85)
Emerg Infect Dis 2019	354	5(1)	62(18)	3(1)	21(6)	243(69)
Emerg Infect Dis 2021 non-COVID-19	306	1(0)	62(20)	1(0)	20(7)	186(61)

Emerg Infect Dis 2021 COVID-19	252	8(3)	12(5)	2(1)	20(8)	160(63)
Emerg Infect Dis 2021	558	9(2)	74(13)	3(1)	40(7)	346(62)
Infect Immun 2019	57	1(2)	11(19)	0(0)	29(51)	56(98)
Infect Immun 2021 non-COVID-19	50	1(2)	16(32)	1(2)	28(56)	50(100)
Infect Immun 2021 COVID-19	0	0	0	0	0	0
Infect Immun 2021	50	1(2)	16(32)	1(2)	28(56)	50(100)
Int J Infect Dis 2019	35	0(0)	4(11)	1(3)	35(100)	35(100)
Int J Infect Dis 2021 non-COVID-19	37	0(0)	4(11)	3(8)	36(97)	37(100)
Int J Infect Dis 2021 COVID-19	513	12(2)	19(4)	22(4)	498(97)	499(97)
Int J Infect Dis 2021	550	12(2)	23(4)	25(5)	534(97)	536(97)
J Antimicrob Chemother 2019	86	1(1)	14(16)	9(10)	28(33)	84(98)
J Antimicrob Chemother 2021 non-COVID-19	101	1(1)	13(13)	8(8)	42(42)	98(97)
J Antimicrob Chemother 2021 COVID-19	25	0(0)	2(8)	3(12)	7(28)	23(92)
J Antimicrob Chemother 2021	126	1(1)	15(12)	11(9)	49(39)	121(96)
J Infect Dis 2019	125	3(2)	9(7)	21(17)	125(100)	125(100)
J Infect Dis 2021 non-COVID-19	114	4(4)	6(5)	12(11)	114(100)	106(93)

J Infect Dis 2021 COVID-19	143	4(3)	3(2)	13(9)	141(99)	138(97)
J Infect Dis 2021	257	8(3)	9(3)	25(10)	255(99)	244(95)
Lancet Infect Dis 2019	39	2(5)	2(5)	9(23)	39(100)	34(87)
Lancet Infect Dis 2021 non-COVID-19	1	0(0)	0(0)	1(100)	1(100)	1(100)
Lancet Infect Dis 2021 COVID-19	40	2(5)	2(5)	10(25)	40(100)	35(88)
Lancet Infect Dis 2021	28	3(11)	4(14)	12(43)	28(100)	27(96)

466 *Bold rows are for the groups and indicators that a statistically significant result $p < 0.005$ was found*
 467 *in a comparison against another group (2021 versus 2019, 2021 COVID-19 versus 2021 non-*
 468 *COVID-19, or 2019 versus 2021 non-COVID-19).*

469

470